Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-13-60 in CEA+ Advanced Solid Tumors
NCT06043466Phase 1Recruiting
- Sponsor
- Chongqing Precision Biotech
- Start
- Aug 2023
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of C-13-60 in colorectal cancer (CRC), esophageal cancer, gastric cancer (GC) and 4 more, sponsored by Chongqing Precision Biotech. Primary endpoints: Dose Limiting Toxicity at 1 month and Maximum Tolerated Dose at 1 month. Started Aug 2023; status: recruiting.
02
Drugs
C-13-60
03
Conditions
colorectal cancer (CRC)esophageal cancergastric cancer (GC)pancreatic cancer (PC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06043466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06043466.